Response assessment in lymphoma

Clinical Radiology

Volumn 63, Issue 2, 2008, Pages 125-135

  Hampson, F A ^a   Shaw, A S ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTRYROSINE F 18; FLUOROTHYMIDINE F 18; GALLIUM 67; METHIONINE C 11; TRACER; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG UPTAKE; HODGKIN DISEASE; HUMAN; LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; TREATMENT RESPONSE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 37849007873     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2007.10.005     Document Type: Review

References (51)

1. Lin A.Y., and Tucker M.A. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. In: Canellos G., Lister T.A., and Sklar J.L. (Eds). The lymphomas (1998), WB Saunders, London 43-61
2. Jerusalam G., Hustinx R., Beguin Y., et al. Evaluation of therapy for lymphoma. Semin Nucl Med 35 (2005) 186-196
3. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244-1253
4. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
5. Callen P.W., Korobkin M., and Isherwood I. Computed tomography evaluation of the retrocrural prevetebral space. AJR Am J Roentegnol 129 (1977) 907-910
6. Carrington B. Lymph nodes. In: Husband J.E.S., and Reznek R.H. (Eds). Imaging in oncology Vol. 2 (1998), Isis Medical Media, Oxford 729-748
7. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and Response to treatment. J Clin Oncol 11 (1993) 1466-1477
8. Fuks J.Z., Aisner J., and Wiernik P.H. Restaging laparotomy in the management of the non-Hodgkin's lymphoma. Med Pediatr Oncol 10 (1982) 429-438
9. Stewart F.M., Williamson B.R., Innes D.J., et al. Residual tumour masses following treatment for advanced histiocytic lymphoma. Cancer 55 (1985) 620-623
10. Surbone A., Longo D.L., DeVita Jr. V.T., et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 6 (1988) 1832-1837
11. Coiffer B., Gisselbrecht C., Herbrecht R., et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7 (1989) 1018-1026
12. Rini J.N., Manalili E.Y., Hoffman M.A., et al. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease. Clin Nucl Med 27 (2002) 572-577
13. Kostakoglu L., Leonard J.P., Kuji I., et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 94 (2002) 879-888
14. Wirth A., Seymour J.F., Hicks R.J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 112 (2002) 262-268
15. Bar-Shalom R., Yefremov N., Haim N., et al. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology 227 (2003) 353-360
16. Friedberg J.W., Fischman A., Neuberg D., et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 45 (2004) 85-92
17. Saski M., Kuwabara Y., Koga H., et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 16 (2002) 337-345
18. Shen Y.Y., Kao A., and Yen R.F. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 9 (2002) 321-325
19. Bossche V.D., Lambert B., De Winter F., et al. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 23 (2002) 1079-1083
20. Hicks R.J., MacManus M.P., and Seymour J.F. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 35 (2005) 165-175
21. Mikhaeel N.G., Timothy A.R., O'Doherty M.J., et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 39 (2000) 543-553
22. Bjurberg M., Gustavsson A., Ohlsson T., et al. FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre. Acta Oncologica 45 (2006) 743-749
23. Cremerius U., Fabry U., Neuerburg J., et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 19 (1998) 1055-1063
24. Zijlstra J.M., Lindauer-van der Werf G., Hoekstra O.S., et al. 18F-fluoro- deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91 (2006) 522-529
25. Juweid M.E., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 (2005) 4652-4661
26. Kostakoglu L., Goldsmith S.J., Leonard J.P., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107 (2006) 2678-2687
27. Allen-Auerbach M., Quon A., Weber W.A., et al. Comparison between 2-deoxy-2- [(18)F]fluoro-d-glucose positron-emission tomography and positron-emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6 (2004) 411-416
28. Freudenberg L.S., Abtoch G., Schutt P., et al. FDG-PET/CT in re-staging patients with lymphoma. Eur J Nucl Med Mol Imaging 31 (2004) 325-329
29. 18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12 (2001) 825-830
30. Hoffmann M., Kletter K., Diemling M., et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose (F18-FDG) does not visualise extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10 (1999) 1185-1189
31. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of pre transplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102 (2003) 53-59
32. Kazama T., Faria S.C., Varavithya V., et al. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. RadioGraphics 25 (2005) 191-207
33. Patz Jr. E.F., Lowe V.J., Hoffman J.M., et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-glucose. Radiology 191 (1994) 379-382
34. Inoue T., Kim E.E., Komaki R., et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36 (1995) 788-793
35. Bury T., Corhay J.L., Duysinx B., et al. Value of FDG-PET in detecting residual or recurrent non small cell lung cancer. Eur Respir J 14 (1999) 1376-1380
36. Keidar Z., Haim N., Guralnik L., et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 45 (2004) 1640-1646
37. Lapela M., Eigved A., Jyrkkio S., et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 36 (2000) 858-867
38. Lowe V.J., Boyd J.H., Dunphy F.R., et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 18 (2000) 651-658
39. Greven K.M., Williams III D.W., McGuirt Sr. W.F., et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23 (2001) 942-946
40. Porceddu S.V., Jarmolowski E., Hicks R.J., et al. Utility of positron emission tomography for detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 27 (2005) 175-181
41. Yao M., Graham M.M., Smith R.B., et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys 60 (2004) 1410-1418
42. Pieterman R., van Putten L.W.G., Meuzelaar J.J., et al. Preoperative staging of non- small cell lung cancer with positron-emission tomography. N Engl J Med 343 (2000) 254-261
43. 18F] fluoro-2-deoxy-d-glucose: correlation with CT. Radiology 190 (1994) 111-116
44. Avril N., Rose C.A., Schelling M., et al. Breast imaging with postitron emission tomography and fluorine-18-fluorodeoxyglucose: use and limitations. J Clin Oncol 18 (2000) 3495-3502
45. Tyler D.S., Onaitis M., Kherani A., et al. Positron emission tomography scanning in malignant melanoma. Cancer 89 (2000) 1019-1025
46. Abrey L.E., Batchelor T.T., Ferreri A.J.M., et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J clin Oncol 23 (2005) 5034-5043
47. Gaspirini M.D., Balzarini L., Castellani M.R., et al. Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 72 (1993) 577-582
48. Devizzi L., Maffioli L., Bongante V., et al. Comparison of gallium scan, computed tomography and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 8 Suppl. 1 (1997) 53-56
49. Griffiths J.R., Tate A.R., Howe F.A., et al. Magnetic resonance spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur J Cancer 38 (2002) 2085-2093
50. 31P MR spectral patterns and reproducibility in cancer patients studied in a muti-institutional trial. NMR Biomed 19 (2006) 504-512
51. Rasey J.S., Grierson J.R., Wiens L.W., et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43 (2002) 1210-1217